Update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
28/05/2018 – AB Science is evaluating the possibility to resubmit the application based on the final results from study AB10015.
Annual Financial Results as of December 31, 2017
30/04/2018 – AB Science reports on its annual financials as of 31 December 2017 and provides an update on its activities.
CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
19/04/2018 – AB Science will provide additional data through a reexamination procedure
Corporate Presentation
13/03/2018 – Current status and perspective for 2018.
IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no requirement to increase the study sample size
04/01/2018 – Additionally, the IDMC did not report any safety concern with masitinib in the study population.
Human Medicine – Inflammatory diseases
European Hematology Association June 2017 22/06/2017 – MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBOCONTROLLED, PHASE 3 STUDY
Human Medicine – Oncology
Abstract O. Hermine Industry’s Perspective 2016 01/07/2016 – Development of masitinib, a novel tyrosine kinase inhibitor and immunotherapeutic, for the treatment of peripheral T-cell lymphoma
Mast Cells as a Target
Montagne-Neuron-2015 21/01/2015 – Blood-Brain Barrier Breakdown in the Aging Human Hippocampus Volonte CNSND-DT Author corrected PROOFS 15/12/2014 – New Kid on the Block: Dœs Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis? PlosOne – Mast Cells in Gastric Cancer 08/09/2014 – Intratumor IL-17-Positive Mast Cells are the major source of the IL-17 that is…
Basic Research
Comparative analysis of the kinase selectivity profile of masitinib versus other TKIs 25/07/2014 – The knowledge of the selectivity of PKIs is a critical point for the development of optimal safe and well tolerated […] PLoS ONE 2009 Dubreuil – MASITINIB A POTENT c-KIT INHIBITOR 30/09/2009 – Masitinib (AB1010), a Potent and Selective Tyrosine Kinase…
Human Medicine – Central Nervous System Diseases
Naunyn-Schmiedeberg’s Arch Pharmacol 2014 Kocic – MASITINIB IN STROKE 26/10/2014 – Neuroprotective effect of masitinib in rats with postischemic stroke BMC Neurology 2012 Vermersch – MASITINIB IN PROGRESSIVE MS 12/06/2012 – Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study PLoSONE 2011 Moura – MASITINIB AND DEPRESSION IN MASTOCYTOSIS 21/10/2011 – Depression…